Global Hologic Mammography Market 2025 – 2034

Reports Description

As per the Hologic Mammography Market analysis conducted by the CMI Team, the global Hologic Mammography market is expected to record a CAGR of 10.23% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 3.27 Billion. By 2034, the valuation is anticipated to reach USD 7.87 Billion.

Overview

The mammography market is evolving at the crossroads of superior imaging technology, AI-enabled diagnoses, and value-based care models. As a leader in women’s health imaging, Hologic offers a full range of services, from full-field digital mammography (FFDM) to digital breast tomosynthesis (DBT) to contrast-enhanced mammography and biopsy systems. These technologies allow early detection with better diagnostic accuracy and may tailor the care of high-risk treatment to complex breast tissue.

Early-stage breast cancer screening being globally promoted, a rise in incidence, and increased funding toward preventive healthcare initiatives push the demand for high-precision imaging systems in North America, Europe, and fast-growing Asia-Pacific economies. Countries with growing national screening programs and initiatives directed toward population health, such as Germany, Japan, South Korea, and India, are increasingly capable of deploying high-grade DBT and AI-based solutions, with the strong market penetration for Hologic.

The company constantly innovates. The arrival of the Mammomat B.brilliant (by Siemens Healthineers, acting as competition) and the Genius™ 3D Mammography® Exam from Hologic has set new standards in breast imaging for low-dose acquisition, synthetic 2D reconstruction, and radiologist workflow optimization. With newer programs for AI-driven lesion detection (3DQuorum, Genius AI Detection), reading time is further reduced whilst improving diagnostic consistency.

Sustainability and smart infrastructure are thus undergoing market reframing. Hologic is injecting energy-efficient systems, modular design, and cloud-based image sharing platforms so that all align with hospital decarbonization objectives and digital health transformation mandates. Other emerging trends include portable mammography units for rural outreach and subscription-based imaging services (equipment + AI + analytics) that enable outpatient centers and startups on a tight budget.

The mammography ecosystem places a lean toward an integrated diagnostics platform with AI developer, healthcare provider, and EHR vendor partnerships to ensure reporting, image sharing, and remote diagnostics. Further building Hologic’s presence as a force for equitable healthcare are public-private partnerships directed at improving access within underserved populations.

Hence, the Hologic mammography market no longer stands for mere machines; rather, it is geared toward precision diagnostics, intelligent automation, population health enablement, and sustainable innovation. This gives the company a vantage point to serve a grown, old, and increasingly AI-intertwined universal healthcare system.

Key Trends & Drivers

The Hologic Mammography market Trends have tremendous growth opportunities due to several reasons:

• Early Diagnosis and Preventive Healthcare Under the Spotlight: Since breast cancer continues to be the most common cancer afflicting women worldwide, governments and health systems now emphasize screening at the early stage and regular diagnostics within their national health schemes. 3D Mammography® by Hologic, being highly sought in the developed United States, being a chief, is generally considered the finest diagnostic procedure, which offers better detection ability with fewer false positives.

• Further Technological Advancements in the Domain of Digital Breast Imaging with AI Integration: The transition from 2D to digital Breast Tomosynthesis has offered diagnostic precision never achieved before, especially for dense breast tissues. With solutions like Clarity HD, 3DQuorum™, Genius AI Detection, and others, Hologic is leading this transition by reducing image noise, improving lesion visualizations, and optimizing radiologist workflows. AI-powered tools now perform automated analysis, reduce reading times, and increase reproducibility across clinics. In this vein, enabling image sharing from the cloud coupled with interoperable PACS solutions allows for remote diagnoses, which is a huge growth enabler for teleradiology and rural screening programs.

• An Increasing Incidence of Breast Cancer and Hence Rising Awareness: An increasing incidence of breast cancer, particularly amongst a mature population in North America, Western Europe, Japan, and South Korea, has greatly widened the addressable market. Hologic’s portable, compact mammography units and subscription-based service models are considered to be suitable for these markets, with their constraints in affordability and infrastructure to achieve massive access and compliance.

Key Threats

The Hologic Mammography market has a number of primary threats that will influence its profitability and future development. Some of the threats are:

• High Cost of Equipment and Lack of Affordability in Emerging Markets: Advanced breast imaging systems, such as Hologic’s 3D Tomosynthesis and DBT, are priced much higher than standard 2D machines; while offering superior diagnostic accuracy, the high upfront costs of installation, maintenance, and training prevent a wider adoption, especially in cost-conscious or underfunded public health systems. In the LMIC setting, the lack of a reimbursement framework, coupled with budgetary constraints, hinders its larger deployment, sitting on the sidelines of Hologic’s earnest market expansion.

• Operational Constraints and Shortage in Specialists: Operating mammographic systems requires radiologic technologists and radiologists trained in interpreting digital images, in addition to modification of existing facilities for safety in some cases. Installation can be delayed by workflow concerns and resistance to change from clinicians unfamiliar with any new system, including those employing AI or high-resolution technology.

• Regulatory Complexity and Data Security Concerns: The regulatory process of medical devices across multiple jurisdictions (FDA, CE, CDSCO, etc.) results in long lead times that ultimately increase compliance costs. Further adopting AI and digital platforms in Hologic’s mammography solutions would raise cybersecurity concerns as well as patient data protection issues, especially in countries where data protection laws are still evolving. This poses a hurdle in the adoption of these technologies by healthcare providers who view digital vulnerabilities or regulatory ambiguities with skepticism.

Opportunities

• Workflow automation and diagnostic transformations are implemented by AI integration: The automatic analysis of images, risk stratification, and diagnostic precision make AI-assisted mammography almost the final step in breast cancer detection. Through several partnerships and acquisitions, including ones for iCAD’s AI assets, Hologic is enriching its solution portfolio to provide real-time decision support, triage prioritization, and lesion detection. With the increasing weeks in radiology work worldwide and especially in markets created by it, there arises enhanced productivity and enhanced efficiency for radiologists from AI-enhanced systems, which in turn gives more room for added value in selling.

• Increased awareness of breast cancer screening and government initiative: With the global health movement and government mandate for early detection of breast cancer, mammography screening programs are being expanded. Markets of Asia-Pacific, Latin America, and the Middle East are increasingly financing breast screening through public-private partnerships. With a well-established name for quality and innovation, Hologic is well-positioned to become the vendor of choice for such programs, primarily through value-based procurement and screening-as-a-service.

• The emergence of point-of-care and mobile mammography units: Portable mammography precludes screening in distant or underserved areas. There is slow growth in demand for battery-powered or mobile mammography systems. With its history in designing compact systems and mobile deployments, Hologic is well-positioned to capture this market. Also, partnering with NGOs, diagnostic labs, and telemedicine platforms presents an opportunity to further expand their outreach, especially in developing countries where breast cancer screening penetration is very low.

Category Wise Insights

By Technology

• Digital Mammography (2D): Since its emergence as the bedrock of any breast-cancer-screening program internationally, with relatively cheaper solution costs for early detection of abnormalities, 2D mammography systems are progressively falling out of demand in developed countries, whereas emerging economies prefer their use. However, because of their low costs and easy operation requiring little infrastructure, 2-D digital mammography systems hold higher market shares in developing countries. In countries with budgetary constraints or lower population density, it finds usage as a practical tool in conducting nationwide screening programs. As these healthcare systems start adopting imaging modalities of improved accuracy, the long-term growth of this segment is set to come to a halt.

• Digital Breast Tomosynthesis (3D Mammography): With greater rates of cancer detection and lower false positives, especially in women with dense breasts, demand for 3D mammography is on the rise. Hologic continues to dominate the market, with the rapid adoption of its 3Dimensions™ systems across North America, Europe, and selected regions in the Asia-Pacific. DBT is increasingly recognized as the breast imaging standard, with favorable reimbursement decisions attained in the U.S., Germany, and Australia. As clinical validation and patient preference grow, the installed base as well as value contribution from 3D systems is expected to far exceed that of 2D systems. Integration of DBT with AI and biopsy technologies is, meanwhile, entrenching it in a high-end market segment.

• Contrast-Enhanced Mammography (CEM): Offering functional imaging to accompany anatomical information, contrast-enhanced mammography is just a notch below MRI in performance but way cheaper and more integrated into the workflow. CEM is garnering growing clinical interest in the interrogation of indeterminate findings and staging of known cancers, especially where MRI is contraindicated or unavailable. While niche in the beginning, the adoption of the technique is now growing and mainly concentrated in specialized breast clinics and academic hospitals. The sail appears to be in favorable wind, with current-age clinical trials backing its diagnostic correctness and cost-effectiveness. Further advancements in contrast-based systems backed by Hologic would place the company at the forefront of this emerging field, especially as AI-aligned tools help improve CEM interpretation.

• AI-Enhanced Systems: AI is rapidly turning mammography from a pure diagnostic tool into a decision support and risk assessment platform. AI mammographic systems demand huge patronage in developed markets, which are acute with a shortage of radiologists and with increasing screening. The systems help for better interpretation, for less reading time, and for triaging patients into higher risk. With more regulatory approvals and radiologists slowly getting accustomed to trusting AI outputs, this technology will, in all probability, become an established component of mammographic platforms. This segment stands at the cusp of an exponential rise as health moves to the domain of personalized diagnostics and preventive screening. In the next five to ten years, mammography systems are likely to be very strongly differentiated by AI.

By Product Type

• Mammography Systems: These full mammography systems dominate the market, as their functions in screening and diagnosis are indispensable in breast care. The 3Dimensions™ and Dimensions™ platforms by Hologic have found favor owing to their integrated imaging, biopsy, and AI modules. Buyers seem concentrated mainly in the hospital and specialty imaging center markets, in need of scalable, upgradeable platforms. Government screening programs and aging infrastructure replacements in developed nations have further driven demand for full mammography systems. The replacement market for the system is presently being lifted by moves to switch to alternatives in 3D mammography and AI features, making this area the highest-grossing product segment in the foreseeable future.

• Biopsy Systems: Breast biopsy systems help diagnose and thus form treatment decisions. These stereotactic and tomosynthesis-guided biopsy systems are winning the market up front due to their prowess and the evolving imaging platform. Image-guided biopsy systems rise in demand with the rise of minimally invasive diagnostic procedures and an increasing preference for outpatient settings. Increasing awareness regarding breast cancer and screening rates also should ramp up biopsy volumes worldwide, particularly for North America, Western Europe, and Urban Asia. This segment is expected to grow at a steady pace, especially from AI integrations, as biopsy technologies become simultaneously more automated and less invasive.

• Workstations & Software: Workstations and software platforms have played and continue to play a key role in image interpretation, diagnostics, and data management. Hologic is building software solutions increasingly embedded with AI to aid radiologists in finding abnormalities, comparing prior exams, and automating workflows. This segment is becoming important as the digitization of healthcare, cloud-based health records, and remote reading become a reality. Software revenues are also recurring, which offers long-term value for vendors. The demand for interoperable, vendor-neutral software is growing, especially among large hospital chains and imaging groups. Over time, the segment is expected to evolve from a standalone workstation system to a cloud-based AI-integrated ecosystem, thereby establishing opportunities for new revenue concepts.

• Accessories & Detectors: Often overlooked, they are essential components of imaging that contribute to good optics and patient comfort. Detectors of the high-resolution variety and special compression paddles dictate one-third of the quality of an image and two-thirds of the diagnosis. Due to a push for better patient outcomes and experience, the need for ergonomic accessories, low-dose detectors, and tancy-compatible components is growing. As the installed base of mammography systems grows worldwide, the aftermarket accessories will remain a steady revenue stream for the industry. Further innovations in detector materials and the miniaturization of hardware may direct the industry toward several new avenues in portable and modular imaging units.

By End User

• Hospitals: Hospitals are the biggest end-user segment on account of heavy patient burden, integrated care infrastructure, and manpower availability. Most hospitals tend to buy a full-featured, high-end system, say the 3Dimensions™ platform of Hologic, along with biopsy modules, plus AI modules. Highly specialized imaging implementation is reported, especially at tertiary or academic hospitals providing comprehensive cancer care. Going forward, hospitals will stay the main revenue driver for Hologic, notably as government-sponsored healthcare spending is on the rise and hospitals are now digitizing their radiology departments.

• Diagnostic Imaging Centers: Outpatient diagnostic imaging centers have become the current fashion of breast cancer screening, offering faster service with the cheapest rates than hospitals. These centers work under some contracts with the national screening programs or insurance providers. There has been the highest demand for 3D medium-tier systems with software enhancements in this segment. Competing on patient throughput and quality of service, these centers are increasingly investing in AI-enabled systems and biopsy add-ons. The shift toward decentralizing imaging services at community centers will serve to further fuel growth for this segment.

• Breast Care Clinics & Specialized Oncology Centers: Breast care clinics are highly specialized centers dedicated exclusively to women’s health and early adopters of newer technologies. These facilities invest in services and solutions at the highest level of quality, providing the whole spectrum, from screening to biopsy to risk assessment. Hologic’s integrated platforms are well placed in this segment, more so with clinics moving increasingly toward personalized screening programs based on genetic and density-based risk profiling. Growing awareness and patient demand for dedicated care environments will see this segment grow strongly over the next decade.

• Academic & Research Institutes: Much smaller in number, academic and research institutes play a big role in validation and are among the earliest adopters of the technology. Those institutes tend to be some of the first to test Hologic’s AI-based modules, advanced biopsy instruments, and contrast approaches to imaging. Their validation of the clinical studies and publication of them governs the direction of adoption throughout hospitals and imaging centers. The demand for data-rich systems and customizable software solutions is higher in this segment, which assesses Hologic’s research partnership as long-term strategic value.

Impact of Latest Tariff Policies

Trade and tariff shifts are, albeit quietly, redefining the workings of the global mammography market, influencing everything from equipment sourcing to component manufacturing and AI-augmented imaging systems. In mid-2024, the United States imposed heavy tariffs up to 55% on Chinese electronics and precision parts, thereby increasing prices for semiconductors, X-ray detector components, and image-processing modules- the group of three that go into assembling top-end mammography platforms such as Hologic 3D systems. Cost pressure, hence, spells a greater burden for entities operating on a manufacturing-engineered or supply-reliant base in China.

In contrast to this, the post-Brexit world sees a regulatory divergence coupled with heightened customs scrutiny for Class II medical devices, border delays, and backlogs in documentation, all crippling the prompt shipment of mammography systems, spare parts, and consumables, thus hampering services in the UK and its vicinity. Further, those delays for CE-marked upgrades and licenses of AI-based software have compounded deployment cycles for Hologic and its competitors.

As a counter-reaction, both Hologic and the other big OEMs are gearing towards a nearshoring paradigm, augmenting manufacturing capacities in North America. America and the EU are forging new sourcing partnerships with Japan, South Korea, and ASEAN nations. Meanwhile, a few of the outpatient imaging providers are choosing to lock in long-term service contracts and predictive maintenance models as shields against hardware sourcing volatility.

This shift in tariffs is triggering the structural metamorphosis toward local assembly, modular imaging systems, and the delivery of AI-as-a-service with resilience, flexibility, and regulatory agility as the watchwords in the Hologic mammography market.

Report Scope

Regional Perspective

The Hologic Mammography market is divided across different regions such as North America, Europe, Asia-Pacific, and LAMEA. This is a cursory overview of each region:

• North America: With the highest share, the North American mammography market is led by very high healthcare expenditure, technological advances, and awareness level of breast cancer screening. Hologic’s 3D digital mammography system (tomosynthesis) is especially accepted in the United States with the FDA approval and its listing for reimbursement by Medicare. The demand is further supported by recommendations for screening on an annual basis by several bodies, including the American Cancer Society and the U.S. Preventive Services Task Force (USPSTF). Integration of AI-enhanced diagnostic software in newer mammography installations seems to be increasing as well, with such AI-enhanced systems assisting radiologists both in early detection and efficient management of the workflow. A high insurance uptake rate and strong hospital networks in the U.S. and Canada further reinforce the dominance of Hologic in this region. Yet, with a great level of market penetration, new sales are likely to be slower due to the high replacement costs of existing digital systems, transitioning upgrades, and service contracts to a much bigger revenue channel compared to new installations.

• Europe: With several countries having made intensive investments toward breast cancer screening programs, some of which now comprise 2D and 3D mammography installations, Europe is a mature mammography market for Hologic systems, which is constantly evolving and maturing. This European market is also aided by the EU initiatives on population-based breast cancer screening recommendations and Horizon Europe-type projects aimed at funding diagnostic innovation. Also assisted by Hologic’s strong brand name and regulatory approvals, including CE Marking, accelerated adoption of AI-based interpretation tools took place, specifically in private diagnostic centres and teaching hospitals. Meanwhile, there are some public healthcare systems that may go for refurbished equipment or competitive bids from low-cost OEMs due to budget constraints. However, Hologic’s continued evolution in AI, cloud-based analytics, and digital workflows could give it leverage in public procurement if it can demonstrate cost efficiency.

• Asia-Pacific: The Asia-Pacific region stands as the fastest-growing Hologic mammography market, as health awareness increases, access to diagnostics improves, and governments work on early detection of cancer. Countries like China, India, Japan, South Korea, and Australia have been investing heavily in digital healthcare infrastructure and women’s health initiatives. The major markets have remained Japan and South Korea because of early high-capacity mammography systems till now, while India and Southeast Asia, with cancer screening programs from the government, have been expanding the market. With strategic placement of Hologic in the regions, supported by portable digital mammography units with AI tools, the operator can make further inroads here. Challenges remain: uneven rural accessibility, a low number of radiologists, and price sensitivity to bear. In the next decade, the region could gradually evolve towards hybrid public-private models in which advanced imaging is being deployed in urban precincts with mobile units addressing rural gaps.

• LAMEA (Latin America, Middle East, and Africa): The LAMEA region provides quite a diversified but relatively underpenetrated market for Hologic mammography products. Digital mammography and tele-radiology are being introduced, thanks to various public-private health partnerships and international health initiatives, into public hospitals and mobile health vans. Hologic’s strongest recommendation would lie in the compact and yet AI-compatible digital systems, which would better suit centralized urban centers. In the Middle East, wealthy Gulf countries such as the UAE and Saudi Arabia are pouring money into women’s health with advanced and high-tech hospitals, promising demand for Hologic 3D systems and diagnostic workstations. But in African countries, access tends to be limited to the main urban centers or donor-funded projects. While infrastructure gaps, limited radiologist manpower, and funding challenges continue to hamper the widespread adoption, there are initiatives headed by the WHO and local governments for pushing awareness and diagnostic infrastructure development. It is this deployment of low-maintenance, portable mammography units and cloud connectivity that would stimulate the faster rate of adoption of the market in remote and underserved locations.

Key Developments

In recent years, the Hologic Mammography market has experienced several crucial changes as the players in the market strive to grow their geographical footprint and improve their product line and profits by using synergies.

• In July 2025, SimonMed Imaging will launch two AI-assisted mammography services, Mammogram+ and Mammogram+ Heart, to push early detection of breast cancer and cardiovascular risk assessment.

• In April 2025, CureMetrix garnered expanded FDA clearance for its cmAngio® AI software (v1.6), now approved for use with mammography platforms of Hologic and GE Healthcare. This newer version creates a wider platform for AI detection of Breast Arterial Calcifications (BAC), improving early cardiovascular risk screening based on conventional mammograms and elevating the competitiveness of the AI integration into Hologic mammography systems.

• In January 2025, Siemens Healthineers announced the Mammomat B.brilliant mammography system’s first installation in the U.S. at GRACE Breast Imaging & Medical Spa in Iowa. This represents the first market arrival for Siemens’ mammography platform that has been fully rethought in over a decade and carries great promise in bringing forth a new dimension of innovation and competition to the mammography market, retailing advanced acquisition of 3D images, digital breast imaging, biopsy capabilities, and titanium contrast-enhanced mammography.

• In November 2024, GE HealthCare introduced its latest release of the Pristina Via mammography system, engineered to enhance the breast-screening experience of both patients and technologists. The Pristina Via is a significant upgrade to the Senographe Pristina platform from the vendor-neutral assertion of prior pictures to lower radiation doses across all breast thicknesses.

• In November 2024, Hologic, Inc. officially launched the Envision Mammography Platform at RSNA, offering patients a fast Hologic 3D mammogram with an industry-leading scan time of 2.5 seconds.

• In June 2024, FUJIFILM’s India Healthcare Division will launch its first Skill Lab in collaboration with NM Medical Mumbai to provide advanced training in full-field digital mammography technologies to radiographers and radiologists.

These important changes facilitated the companies widening their portfolios, bolstering their competitiveness, and exploiting the possibilities for growth available in the Hologic Mammography market. This phenomenon is likely to persist since most companies are struggling to outperform their rivals in the market.

Leading Players

The Hologic Mammography market is moderately consolidated, with a large number of product providers globally. Some of the key players in the market include:

• GE Healthcare
• Hologic Inc.
• Siemens Healthineers
• Philips Healthcare (Koninklijke Philips N.V.)
• Fujifilm Holdings Corporation
• Canon Medical Systems Corporation
• Carestream Health Inc.
• Planmed Oy
• Metaltronica SpA
• Konica Minolta Inc.
• Aurora Imaging Technologies Inc.
• Dilon Technologies Inc.
• SonoCiné Inc.
• Seno Medical Instruments Inc.
• Delphinus Medical Technologies Inc.
• IM3/S I.M.S. Srl
• Christie Innomed
• General Medical Merate S.p.A.
• Analogic Corporation
• NovaRad
• Others

The Hologic Mammography Market is best described as a moderately consolidated landscape, with a few key players commanding a good chunk of the global share; there is still, however, space for competition, especially in developing countries and in tier 2 healthcare settings. Hologic Inc. stands at the top, largely considered the global mammography system leader, especially in 3D digital breast tomosynthesis (DBT) technology. Hologic derives its supremacy from having the broadest and most advanced product portfolio, which also diminishes competition with further AI-based image interpretation, computer-assisted detection (CAD), and integrated breast biopsy solutions-laden mammography platforms. They have much traction in high-income countries like the US, UK, Germany, and France, wherein precision and workflow optimization relative to advanced screening protocols are favored in hospitals and diagnostics.

Even as Hologic dominates the market, it is not entirely consolidated yet. There are other big players such as Siemens Healthineers, GE HealthCare, FUJIFILM Holdings, Canon Medical Systems, and Philips Healthcare, pronging the competitive landscape with offerings in both expensive high-end 3D options as well as cheaper 2D and hybrid units. These providers compete with one another with regard to innovation, regional service networks, price differentiation, and integration of imaging software. For example, advances granted Siemens and GE the ability to embed AI (Artificial Intelligence) and cloud-based diagnostic techniques into their mammography systems, which were supposed to improve the speed and accuracy of diagnoses but also supported workflows tied to telehealth and remote review.

The competitive structure becomes fragmented in emerging markets like Asia Pacific, Latin America, and parts of Eastern Europe and Africa, where price weighs significantly more than advanced technologies. These three markets all witness homegrown and regional producers, perhaps with government backing, delivering cheap 2D mammography devices focused on rudimentary screening requirements. Here, Hologic faces tough competition from smaller players offering flexible pricing and service contracts, along with mobile mammography units for remote regions. Yet, even in these areas, the tide is shifting toward the adoption of 3D tomosynthesis with incidence in tertiary cardiac systems and private diagnostic chains, so starkly indicating long-term competition with rising domestic beneficiaries.

The service and software integrated model is gaining acceptance in this market, where players differentiate themselves not just based on hardware, but also on aspects such as digital platform offerings, AI diagnostics, cloud PACS integration, biopsy compatibility, and end-to-end breast health management systems. Hologic leads this transformation with Genius™ AI Detection and SmartCurve™ Technology for greater patient comfort and diagnostic confidence. However, as their competitors continue to ramp up R&D efforts, especially in AI and image processing, one sees the growing competition emerging, especially as reimbursement and regulatory approvals worldwide are slow to catch up with the technology.

The Hologic Mammography Market is segmented as follows:

By Technology

• Digital Mammography (2D)
• Digital Breast Tomosynthesis (3D)
• Contrast-Enhanced Mammography
• AI Enhanced Systems

By Product Type

• Mammography Systems
• Biopsy Systems
• Workstations & Software
• Accessories & Detectors

By End User

• Hospitals
• Diagnostic Imaging Centers
• Breast Care Clinics & Specialized Oncology Centers
• Academic & Research Institutes

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America